A clinician's perspective: Novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation - Full speed ahead or proceed with caution?

Vascular Health and Risk Management

Volumn 10, Issue , 2014, Pages 507-522

  Yang, Eugene ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Anticoagulant monitoring; Anticoagulant reversal; Apixaban; Dabigatran; Edoxaban; Rivaroxaban

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; WARFARIN;

ANTICOAGULATION; BLEEDING; BRAIN HEMORRHAGE; CARDIOVERSION; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; DRUG CHOICE; DRUG COST; DRUG DETERMINATION; DRUG EFFICACY; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; EMBOLISM; EMERGENCY SURGERY; HEART ATRIUM FIBRILLATION; HUMAN; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SYSTEMIC DISEASE; THROMBOEMBOLISM; TREATMENT RESPONSE; ATRIAL FIBRILLATION; CHEMICALLY INDUCED; COMPLICATION; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; DRUG SUBSTITUTION; ECONOMICS; EVIDENCE BASED MEDICINE; ORAL DRUG ADMINISTRATION; PERIOPERATIVE PERIOD; RISK FACTOR; STROKE; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; DRUG SUBSTITUTION; EVIDENCE-BASED MEDICINE; HEMORRHAGE; HUMANS; PATIENT SELECTION; PERIOPERATIVE CARE; RISK FACTORS; STROKE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84907342888     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S68117     Document Type: Review

References (87)

1. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J.2010;31: 2369-2429.
2. Colilla S, Crow A, Simon T, et al. Projected estimates of prevalence and annual growth rate of atrial fibrillation in the United States from a dynamic age-period progression model. Circ Cardiovasc Qual Outcomes.2012;5:A2056.
3. Wolf PA, Abbott RD, Kannel WB. Atrial f ibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
4. [No authors listed]. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med.1994;154:1449-1457.
5. Bristol-Myers Squibb. Coumadin ® (prescribing information). Available from: http://packageinserts.bms.com/pi/pi_coumadin.pdf. Accessed October11,2013.
6. Boehringer Ingelheim. Pradaxa® (dabigatran etexilate) capsules (prescribing information). Available from: http://bidocs. boehringer-ingelheim.com/BIWebAccess/ViewServlet. ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/ Pradaxa/Pradaxa.pdf. Accessed September18,2013.
7. Bristol-Myers Squibb. Eliquis® (apixaban tablets, prescribing information). Available from: http://packageinserts.bms.com/pi/ pi_eliquis.pdf. Accessed March20,2014.
8. Janssen Pharmaceuticals. Xarelto ® (rivaroxaban tablets, prescribing information). Available from: http://www.xareltohcp.com/sites/default/ files/pdf/xarelto_0.pdf#zoom=100. Accessed October8,2013.
9. Mendell J, Zahir H, Matsushima N, et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs.2013;13:331-342.
10. Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50:743-753.
11. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med.2009;361:1139-1151.
12. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med.2011;364:806-817.
13. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med.2011;365: 981-992.
14. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med.2011;365:883-891.
15. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med.2010;363:1875-1876.
16. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med.2013;369:2093-2104.
17. Alexander JH, Levy E, Lawrence J, et al. Documentation of study medication dispensing in a prospective large randomized clinical trial: experiences from the ARISTOTLE trial. Am Heart J.2013;166: 559-565.
18. Food and Drug Administration. Center for Drug Evaluation and Research. Application number202155Orig1s000. Summary review. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/ nda/2012/202155Orig1s000SumR.pdf. Accessed June3,2013.
19. Bristol-Myers Squibb, Pfizer EEIG. Eliquis® (apixaban tablets) Summary of product characteristics. Available from: http://www.ema. europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/ human/002148/WC500107728.pdf. Accessed June2,2014.
20. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med.2012;172:397-402.
21. Hohnloser SH, Oldgren J, Yang S, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY trial. Circulation.2012;125:669-676.
22. Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace.2013;15: 625-651.
23. Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med.2012;366:864-866.
24. Legrand M, Mateo J, Aribaud A, et al. The use of dabigatran in elderly patients. Arch Intern Med.2011;171:1285-1286.
25. Wood S. Deaths prompt dabigatran safety advisory in Japan. Available from: http://www.medscape.com/viewarticle/748143. Accessed April24, 2014.
26. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation.2011;123: 2363-2372.
27. European Medicines Agency. Questions and answers on the review of bleeding risk with Pradaxa (dabigatran etexilate). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/ Medicine_ QA/2012/05/WC500127768.pdf. Accessed November1,2012.
28. Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med.2013;368:1272-1274.
29. US Food and Drug Administration. Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin. May13,2014. Available from: http://www.fda.gov/downloads/ Drugs/DrugSafety/UCM397606.pdf. Accessed June4,2014.
30. Larsen TB, Rasmussen LH, Skjoth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol. 2013;61:2264-2273.
31. Ho JC, Chang AM, Yan BP, et al. Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong. Clin Cardiol.2012;35:E40-E45.
32. Goodman SG, Wojdyla DM, White HD, et al. Predictors of major bleeding risk: insights from the rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation.2011;124:A16903.
33. Piccini JP, Garg J, Patel MR, et al. Management of major bleeding events in patients treated with rivaroxaban vs warfarin: results from the ROCKET AF trial. Eur Heart J. 2014;35:1873-1880.
34. Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33:2821-2830.
35. Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin in the ARISTOTLE trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol. 2014;63:2141-2147.
36. Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost.2010;104:1263-1271.
37. Garcia D, Barrett YC, Ramacciotti E, Weitz JI. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost.2013;11:245-252.
38. Liesenfeld KH, Schafer HG, Troconiz IF, et al. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol.2006;62:527-537.
39. Samama MM, Martinoli JL, Le Flem L, et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost.2010;103:815-825.
40. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis.2012;23:138-143.
41. van Ryn J, Ruehl D, Priepke H, et al. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate. Haematologica.2008;93:148.
42. Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost.2008;6:820-829.
43. Hawes EM, Deal AM, Funk-Adcock D, et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost.2013;11:1493-1502.
44. Becker RC, Yang H, Barrett Y, et al. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban-an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis. 2011;32:183-187.
45. Samama MM, Amiral J, Guinet C, et al. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost.2010;104:1078-1079.
46. Miyares MA, Davis K. Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient. Am J Health Syst Pharm.2012;69:1473-1484.
47. Wolzt M, Weltermann A, Nieszpaur-Los M, et al. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man. Thromb Haemost.1995;73:439-443.
48. Zhou W, Schwarting S, Illanes S, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke.2011;42:3594-3599.
49. Food and Drug Administration. Advisory Committee Briefing Book. Rivaroxaban for the prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ CardiovascularandRenalDrugsAd visoryCommittee/UCM138385.pdf. Accessed February19,2012.
50. Wang X, Mondal S, Wang J, et al. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs.2014;14:147-154.
51. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation.2011;124:1573-1579.
52. Marlu R, Hodaj E, Paris A, et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012;108:217-224.
53. Escolar G, Arellano-Rodrigo E, Reverter JC, et al. Reversal of apixaban induced alterations of hemostasis by different coagulation factor concentrates: studies in vitro with circulating human blood. Circulation. 2012;126:520-521.
54. Crowther M, Kitt M, Lorenz T, et al. A phase2randomized, double-blind, placebo-controlled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitors. J Thromb Haemost.2013;11 Suppl2:30.
55. Crowther M, Mathur V, Kitt M, et al. A phase2randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for FXa inhibitors. Abstract presented at the55th Annual Meeting of the American Society of Hematology, December7-10,2013, New Orleans, LA, USA.
56. Granger C, Alexander JH, Hanna M, et al. Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial. Eur Heart J.2012;33 Suppl:685-686.
57. Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol.2012;59:1168-1674.
58. Patel MR, Hellkamp AS, Lokhnygina Y, et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol.2013;61:651-658.
59. Piccini JP, Stevens SR, Lokhnygina Y, et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol.2013;61: 1998-2006.
60. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative Management of Antithrombotic Therapy: Antithrombotic Therapy and Prevention of Thrombosis,9th ed: American College of Chest Physicians EvidenceBased Clinical Practice Guidelines. Chest.2012;141:e326S-e350S.
61. Larsen TB, Rasmussen LH, Gorst-Rasmussen A, et al. Myocardial ischemic events in "real world" patients with atrial fibrillation treated with dabigatran or warfarin. Am J Med.2014;127:329-336. e4.
62. January CT, Wann LS, Alpert JS, et al.2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary: A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol.2014;pii: S0735-1097(14)01740-01749.
63. Eitel C, Koch J, Sommer P, et al. Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation. Europace.2013;15:1587-1593.
64. Providencia R, Marijon E, Albenque JP, et al. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation. Europace. 2014;16:1137-1144.
65. Sardar P, Nairooz R, Chatterjee S, et al. Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation. Am J Cardiol.2014;113:1173-1177.
66. Stepanyan G, Badhwar N, Lee RJ, et al. Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation. J Interv Card Electrophysiol. 2014;4:33-38.
67. Winkle RA, Mead RH, Engel G, et al. The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2012;23:264-268.
68. Healey JS, Eikelboom J, Douketis J, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation.2012;126: 343-348.
69. Lopes RD, Garcia DA, Wojdyla DM. Use of apixaban and warfarin in patients undergoing invasive procedures: insights from ARISTOTLE. Eur Heart J.2013;34 Suppl:98-99.
70. Ezekowitz MD, Connolly S, Parekh A, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J.2009;157: 805-810.
71. Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation.2011;123:131-136.
72. Flaker G, Lopes RD, Al-Khatib SM, et al. Apixaban and warfarin are associated with a low risk of stroke following cardioversion for atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J. 2012;33:686.
73. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet.2010;376:975-983.
74. Wallentin L, Lopes RD, Hanna M, et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation.2013;127:2166-2176.
75. Camm AJ, Lip GY, De Caterina R, et al.2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J.2012;33:2719-2747.
76. Schulman S, Shortt B, Robinson M, Eikelboom JW. Adherence to anticoagulant treatment with dabigatran in a real-world setting. J Thromb Haemost.2013;11:1295-1299.
77. Sorensen R, Gislason G, Torp-Pedersen C, et al. Dabigatran use in Danish atrial fibrillation patients in2011: a nationwide study. BMJ Open.2013;3.
78. Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J.2011;32:2387-2394.
79. Schulman S, Kearon C, the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3: 692-694.
80. Gu Q, Dillion CF, Burt VL. NCHC Data brief: prescription drug use continues to increase: US prescription drug data for2007-2008. Available from: http://www.cdc.gov/nchs/data/databriefs/db42.htm. Accessed June6,2013.
81. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med.2011;154:1-11.
82. Kamel H, Easton JD, Johnston SC, Kim AS. Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation. Neurology.2012;79:1428-1434.
83. Lee S, Anglade MW, Meng J, et al. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin. Circ Cardiovasc Qual Outcomes. 2012;5:472-479.
84. Lee S, Anglade MW, Pham D, et al. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol.2012;110:845-851.
85. Deitelzweig S, Amin A, Jing Y, et al. Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF and ARISTOTLE trials. J Med Econ.2012;15:776-785.
86. Lip GYH, Kongnakorn T, Phatak H, et al. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. Clin Ther.2014;36:192-210.
87. American College of Cardiology. Registry data shows early patterns for new atrial fibrillation treatments. Available from: http://www.cardiosource.org/News-Media/Media-Center/News-Releases/2012/08/ PINN-AF.aspx. Accessed October15,2012.